Pfizer has agreed to pay $14.5 million to settle False Claims Act allegations related to the marketing of its drug Detrol, according to a news release from the Department of Justice.
This settlement resolves the last of a group of 10 whistleblower suits filed since 2003. The other nine suits were settled or dismissed in 2009 when Pfizer agreed to pay $2.3 billion to resolve civil claims and criminal charges regarding multiple drugs.
This specific settlement resolves allegations that Pfizer illegally marketed Detrol, a drug for the treatment of overactive bladder. Of the $14.5 million recovery, $11.9 million will go to the federal government and $2.6 million to state Medicaid programs. Under the qui tam provisions of the False Claims Act, whistleblowers will receive a $3.3 million share of the federal recovery.
Related Articles on Pharmaceutical Companies and Settlements:
Wisconsin’s Ongoing Lawsuit Against Drugmakers Reaches Nearly $13M in Settlements
Harvard Drug Group Pays $8M to Settle Claims of Failure to Report Suspicious Drug Orders
Teva Loses $144M Damages Claim to Baxter, Must Compensate Infected Patient $500M
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
